8月14日，联影医疗今日收盘127.92元，下跌2.38%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到83.10倍，总市值1054.26亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，联影医疗排 名第103位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13联影医疗83.1083.555.201054.26亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18.2218.241.5139.27亿9奥泰生物18.4419.441.4958.81亿10维力医疗18.4719.732.3243.29亿11鱼跃医疗 20. ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of United Imaging Healthcare, indicating a high price-to-earnings (PE) ratio compared to industry averages [1][2] - As of August 8, the company's stock closed at 130.7 yuan, with a PE ratio of 84.91, significantly higher than the industry average of 55.70 and median of 39.08 [1][2] - The total market capitalization of United Imaging Healthcare is reported at 107.17 billion yuan [1][2] Group 2 - For Q1 2025, the company achieved a revenue of 2.478 billion yuan, reflecting a year-on-year growth of 5.42%, and a net profit of 370 million yuan, with a year-on-year increase of 1.87% [2] - The company's gross profit margin stands at 49.94% [2] - As of March 31, 2025, the number of shareholders increased to 21,435, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

8月4日，联影医疗今日收盘131.29元，下跌1.52%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到85.29倍，总市值1082.04亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，联影医疗排 名第102位。 股东方面，截至2025年3月31日，联影医疗股东户数21435户，较上次增加3165户，户均持股市值35.28 万元，户均持股数量2.76万股。 上海联影医疗科技股份有限公司的主营业务是为全球客户提供高性能医学影像设备、放射治疗产品、生 命科学仪器及医疗数字化、智能化解决方案。公司的主要产品是磁共振成像系统(MR)、X射线计算机断 层扫描系统(CT)、X射线成像系统(XR)、分子影像系统(MI)、医用直线加速器系统(RT)、动物MR、动 物PET/CT、联影云平台、云胶片、云PACS、数字化医疗解决方案。截至报告期末，公司知识产权累计 申请11,502项，累计获得5,882项；报告期内，公司新增知识产权申请1,079项，获707项，其中发明专利 申请766项，发明专利授权465项。 最新一期业绩显示，2025年一季报，公司实现营业收入2 ...

Core Viewpoint - The company, United Imaging Healthcare, has shown a significant increase in stock price and market capitalization, but its price-to-earnings (PE) ratio remains high compared to industry averages, indicating potential overvaluation [1][2]. Company Summary - United Imaging Healthcare's stock closed at 129.71 yuan, up 2.60%, with a rolling PE ratio of 84.26, marking a new low in 18 days and a total market capitalization of 106.90 billion yuan [1]. - The company operates in the medical device sector, providing high-performance medical imaging equipment, radiation therapy products, life science instruments, and digital healthcare solutions [1]. - As of the first quarter of 2025, the company had 117 institutional investors holding a total of 33,436.65 million shares, with a market value of 40.79 billion yuan [1]. Financial Performance - In the first quarter of 2025, the company reported revenue of 2.478 billion yuan, a year-on-year increase of 5.42%, and a net profit of 370 million yuan, up 1.87%, with a gross profit margin of 49.94% [2]. - The company's PE ratio is significantly higher than the industry average of 51.42 and the median of 37.44, indicating a potential premium valuation [2].

Company Overview - Shanghai United Imaging Healthcare Co., Ltd. specializes in providing high-performance medical imaging equipment, radiation therapy products, life science instruments, and digital healthcare solutions globally [1] - The main products include MRI systems, CT systems, XR systems, molecular imaging systems, medical linear accelerators, animal MRI, animal PET/CT, United Imaging Cloud platform, cloud film, cloud PACS, and digital healthcare solutions [1] Financial Performance - For Q1 2025, the company reported revenue of 2.478 billion yuan, a year-on-year increase of 5.42% [2] - The net profit for the same period was 370 million yuan, reflecting a year-on-year growth of 1.87% [2] - The gross profit margin stood at 49.94% [2] Market Position - As of July 2, the company's stock closed at 126.15 yuan, down 1.48%, with a rolling PE ratio of 81.95 times [1] - The total market capitalization reached 103.968 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing the company at the 102nd position in the industry ranking [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 21,435, up by 3,165 from the previous count [1] - The average market value of shares held per shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Intellectual Property - The company has applied for a total of 11,502 intellectual property rights, of which 5,882 have been granted [1] - During the reporting period, the company filed 1,079 new intellectual property applications and received 707 grants, including 766 invention patent applications and 465 granted invention patents [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of United Imaging Healthcare, with a focus on its stock performance and industry comparisons [1][2] - As of June 20, the company's stock closed at 128.46 yuan, with a 1.05% increase, resulting in a rolling PE ratio of 83.45 times and a total market capitalization of 105.87 billion yuan [1] - The average PE ratio for the medical device industry is 47.91 times, with a median of 35.05 times, positioning United Imaging Healthcare at the 105th rank within the industry [1][2] Group 2 - For the first quarter of 2025, the company reported a revenue of 2.478 billion yuan, reflecting a year-on-year growth of 5.42%, and a net profit of 370 million yuan, with a year-on-year increase of 1.87% [2] - The company's gross profit margin stands at 49.94% [2] - United Imaging Healthcare has a total of 11,502 intellectual property applications, with 5,882 granted, and during the reporting period, it filed 1,079 new applications, receiving 707 approvals, including 766 invention patent applications and 465 granted [1]